Major Histocompatibility Complex class I presenting Human T-cell Leukemia Virus type 1-derived epitope (MHC I-HTLV-1 epitope)

The Major Histocompatibility Complex (MHC) class I presenting Human T-cell Leukemia Virus type 1 (HTLV-1)-derived epitope is a specialized molecular complex essential for the immune recognition of HTLV-1 infected cells. HTLV-1 is a human retrovirus primarily infecting CD4+ T cells, leading to severe conditions such as adult T-cell leukemia/lymphoma (ATL) and the chronic inflammatory neurological disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) (PubMed: 21666769). The virus expresses several oncogenic proteins, most notably the Tax protein, which is processed into short peptide fragments and presented on the cell surface by MHC class I molecules, particularly HLA-A*02:01 (PubMed: 25653438). This peptide-MHC (pMHC) complex serves as the primary target for CD8+ cytotoxic T lymphocytes (CTLs), which recognize the complex via specific T-cell receptors (TCRs) to initiate cell-mediated lysis. In therapeutic development, this complex is targeted by TCR-engineered T-cell (TCR-T) therapies and therapeutic vaccines designed to enhance the CTL response against the viral reservoir and malignant cells (PubMed: 33441435). However, therapeutic efficacy can be hindered by viral mechanisms that downregulate MHC expression or by the potential for TCR cross-reactivity with similar self-peptides, posing a risk of off-target toxicity.

Other names

HLA-HTLV-1 peptide complexHTLV-1 pMHCHTLV-1 Tax epitopeHTLV-1 antigen-MHC complexMHC-HTLV-1 peptide complex

Recognition of the peptide-MHC complex by specific T-cell receptors (TCRs) on CD8+ cytotoxic T lymphocytes, triggering the release of perforins and granzymes to induce apoptosis in the target cell (PubMed: 10881010).